Solutions Spotlight: Managing Chloramines in Pharmaceutical Water Systems

As municipal water utilities increasingly shift from free chlorine to chloramine disinfection strategies, pharmaceutical manufacturers are facing new challenges in maintaining consistent, high-purity water systems. While chloramines provide utilities with longer-lasting residual disinfection and reduced formation of regulated byproducts, they also introduce operational risks inside pharmaceutical facilities. As a result, manufacturers are reassessing traditional chloramine removal approaches and exploring more proactive treatment strategies that improve resiliency, monitoring, and long-term operational efficiency.

 

In this episode of Off Script, sponsored by Trojan Technologies, we spoke with Wayne Lem, global applications manager at Trojan Technologies, about the evolving role of UV technology in pharmaceutical water treatment systems. The conversation explores how chloramine shifts at the municipal level are impacting pharmaceutical manufacturing operations, the limitations of traditional approaches like catalytic carbon and reducing chemicals, and how UV-based chloramine destruction can help facilities improve process reliability while reducing maintenance and chemical dependency. Lem also discusses the operational and economic considerations behind UV adoption, the importance of continuous monitoring and validation in regulated environments, and why hybrid, multi-barrier treatment strategies are becoming increasingly important as manufacturers modernize water infrastructure.